Opdivo (Nivolumab) vs Lumakras (sotorasib)

Opdivo (nivolumab) is an immunotherapy drug that works by blocking the PD-1 protein on certain immune cells, thereby enhancing the immune system's ability to detect and fight cancer cells. Lumakras (sotorasib) is a targeted therapy specifically designed to inhibit the KRAS G12C mutation, a specific genetic change found in some cancer cells. The choice between Opdivo and Lumakras would depend on the specific type of cancer, its genetic makeup, and the patient's overall health status, with Lumakras being an option for patients whose tumors have the KRAS G12C mutation and Opdivo being considered for a broader range of cancers, including those without this specific mutation.

Difference between Opdivo and Lumakras

Metric	Opdivo (Nivolumab)	Lumakras (sotorasib)
Generic name	Nivolumab	Sotorasib
Indications	Various types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, among others	Non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody, which helps the immune system attack cancer cells	KRAS G12C inhibitor, targeting the KRAS G12C mutation and inhibiting cancer cell growth and survival
Brand names	Opdivo	Lumakras
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, decreased appetite, cough, dyspnea, constipation, vomiting, and others	Diarrhea, musculoskeletal pain, nausea, fatigue, liver damage, cough, and others
Contraindications	Patients with severe hypersensitivity to nivolumab or any of its excipients	Patients with severe hypersensitivity to sotorasib or any of its excipients
Drug class	Immune checkpoint inhibitor	KRAS G12C inhibitor
Manufacturer	Bristol Myers Squibb	Amgen

Efficacy

Opdivo (Nivolumab) in Lung Cancer Treatment

Opdivo, also known by its generic name nivolumab, is a medication that has shown efficacy in treating certain types of lung cancer. As an immune checkpoint inhibitor, it works by blocking the PD-1 protein on the surface of immune cells, thereby enhancing the immune system's ability to detect and destroy cancer cells. Opdivo has been approved for the treatment of non-small cell lung cancer (NSCLC) after it has shown significant improvements in overall survival rates compared to traditional chemotherapy in several clinical trials. It is particularly effective in patients whose tumors express PD-L1, a protein that can suppress the immune response against cancer cells.

For patients with advanced NSCLC who have progressed on or after platinum-based chemotherapy, Opdivo has become a standard treatment option. Studies have demonstrated that Opdivo can extend the lives of these patients compared to docetaxel, a commonly used chemotherapy drug. The efficacy of Opdivo varies depending on several factors, including the PD-L1 expression level, histology of the lung cancer, and prior treatments the patient has received.

Lumakras (Sotorasib) and Its Role in Lung Cancer

Lumakras, known generically as sotorasib, is a relatively new medication that has been approved for the treatment of lung cancer. Specifically, it targets the KRAS G12C mutation, which is a genetic alteration found in a subset of patients with NSCLC. Lumakras is a KRAS inhibitor that works by directly targeting the mutated protein, thereby inhibiting tumor growth. It is indicated for patients with NSCLC who have the KRAS G12C mutation and have received at least one prior systemic therapy.

The efficacy of Lumakras in lung cancer was demonstrated in a phase 2 clinical trial, where it showed a notable tumor response rate in patients with the KRAS G12C mutation. The trial indicated a significant percentage of patients experienced a reduction in tumor size, and the median duration of response was also promising. Lumakras offers a targeted approach for a previously difficult-to-treat genetic mutation in lung cancer, providing a new avenue of hope for patients with this specific molecular profile.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Lumakras

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom

Access Opdivo or Lumakras today

If Opdivo or Lumakras are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Lumakras

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: